-- Writing the Future of Biologics Presentation
on May 2 --
-- Rapid, Function-Forward mAb Discovery
against a Cell Surface Target via Concurrent Use of Humanized and
Hyperimmune Mice Presentation on May 4 --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced six poster
presentations at PEGS (The Essential Protein Engineering & Cell
Therapy Summit) Boston occurring May 2-6 virtually and in-person at
the Hynes Convention Center in Boston, MA. In addition, Aaron Sato,
Ph.D., chief scientific officer of Twist Bioscience, will present
‘Writing the Future of Biologics’ on May 2 at 2:50 PM ET and Tracey
Mullen, SVP, operations, will present ‘Rapid, Function-Forward mAb
Discovery against a Cell Surface Target via Concurrent Use of
Humanized and Hyperimmune Mice’ on May 4 at 12:30 PM ET. Twist will
also host a networking event on May 4 from 7:00-10:00 PM ET. Visit
https://bit.ly/TwistMixer to register.
“These posters show the depth and breadth of the antibody
discovery and library construction capabilities of Twist Biopharma
against high-impact targets,” said Emily M. Leproust, Ph.D., CEO
and co-founder of Twist Bioscience. “Our next generation libraries
enable antibody discovery for therapies such as CAR-T engineered
cell therapies, which have the potential to change the treatment
landscape for patients. In addition, the data presented on the
discovery of an antibody targeting ADORA2A, a next generation
checkpoint, demonstrate Twist Biopharma’s ability to generate
antibodies independently.”
Poster Number: P003
Advanced Antibody Discovery Workflow to Capture Maximum
Repertoire Diversity
The complexity of antibody therapeutic targets continues to
evolve, which in turn necessitates the evolution of integrated
discovery methodologies. Incorporating state-of-the-art,
high-resolution techniques enables reliable candidate triage more
efficiently than traditional techniques. Major advancements in
critical tools have improved antibody discovery by providing robust
and thorough analysis of target specificity, function, and
developability earlier in the drug development process. Effective
integration of these technologies bolsters the antibody discovery
process and facilitates lead candidate selection within as few as
two months.
Poster Number: P004
In Vivo VHH Discovery Workflow Based on Immunized Alpaca and
Rapid Beacon-Based Single B Cell Screening
VHH antibodies have demonstrated tremendous promise as versatile
building blocks for antibody-based therapeutics, multispecifics and
cell-based biologics due to higher affinity and better access to
hidden epitopes on cell surface targets as compared to conventional
IgG antibodies. Effective integration of advanced tools for
analysis of target specificity, function and developability can
bolster the VHH discovery process and facilitate lead candidate
selection for novel therapeutic modalities against traditionally
challenging targets.
Poster Number: P143
Next Generation Synthetic Libraries for Enzyme Engineering,
Cell Therapy and Gene Editing Technologies
This poster details Twist’s next generation libraries including
CRISPR gRNA libraries, which are an efficient tool for high
throughput gene editing and knockout of molecular targets;
synonymous codon (SynCodon) libraries, which are optimized to
improve protein yields, binding affinity, stability, and expression
of proteins; and T cell receptor (TCR) and chimeric antigen
receptor (CAR) T cell libraries, which can be used in combination
to screen a large scale of module sets.
Poster Number: P144
Discovery of Pre-clinical ADORA2A Antibody with Twist High
Throughput Antibody Discovery Platform
These data detail how Twist used its high-throughput DNA
synthesis platform and a large-scale phage library built based on a
mouse immunization platform from Abveris, a division of Twist
Bioscience, to discover a high-affinity antagonistic ADORA2A
antibody, which in preclinical studies restored T cell activity and
showed anti-tumor activity.
Poster Number: P145
Engineering Synthetic Multivalent VHH Antibodies at
Scale
These data describe Twist’s scalable process for engineering
high affinity mono and bispecific multivalent VHH-Fc antibodies
against the SARS-CoV-2 spike protein.
Poster Number: P146
Leveraging synthetic Library of Libraries to enable effective
antibody discovery against high-impact targets
This poster demonstrates how Twist discovered high-affinity
antibodies for six cytokine or immunomodulatory targets by
constructing synthetic antibody libraries, using phage display to
pan libraries against biotinylated protein targets, and screening
for lead candidates through ELISA binding assays and NGS enrichment
tracking.
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we
can construct proprietary antibody libraries precisely designed to
match sequences that occur in the human body. The Library of
Libraries gives our partners an integral and unbiased resource for
antibody discovery and optimization. This precise and rational
approach to library fabrication combined with sophisticated
bioinformatics and software expertise expedites antibody discovery
by decreasing risk, increasing speed, and lowering the failure rate
for antibody development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
9, 2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005355/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024